Korro Bio, Inc. KRRO
At closeNov 6, 2026, 4:26 PM EST
After hours · Nov 6, 4:26 PM ET
- YTD
- +84.14%
- 1 year
- -54.71%
- Market cap
- 217.20M
- EPS (ttm)
- -8.89
- Shares out
- 9.37M
- Forward P/E
- -4.29
- YTD return
- +84.14%
- 1-year return
- -54.71%
- Volume
- 122.60K
- Avg volume
- 175.81K
- Open
- 14.74
- Previous close
- 14.73
- Day's range
- 14.69 – 15.74
- 52-week range
- 5.28 – 33.84
- Analysts
- Buy
- Price target
- 137.76 (+833.9%)
- Earnings date
- Aug 13, 2024
2Y -40.26 (-73.19%)
Key statistics
- Enterprise value
- 311.72M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.25
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -81.13M
- Total cash
- 137.00M
- Total debt
- 41.78M
- Return on equity
- -74.51%
- Short % of float
- 4.22%
- 50-day average
- 55.42
- 200-day average
- 51.10
Analyst view
Consensus: buy
- Target (low)
- 105.00
- Target (mean)
- 137.76
- Target (high)
- 180.00
- Strong buy4
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -2.60.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -2.55 | -2.26 | +0.29 | +11.37% |
| Aug 13, 2024 | Jun 1, 2024 | -2.40 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | -2.40 | -2.43 | -0.03 | -1.25% |
| May 14, 2024 | Mar 1, 2024 | -2.36 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -2.36 | -2.44 | -0.08 | -3.39% |
| Mar 29, 2024 | Dec 1, 2023 | -2.33 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 22, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 18, 2024 | Jones Trading | init | — | Buy |
| Nov 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 21, 2024 | RBC Capital | main | Outperform | Outperform |
| Oct 21, 2024 | Raymond James | init | — | Strong Buy |
| Oct 18, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- korrobio.com
News
Korro Bio Q3 EPS $(0.98) Beats $(1.26) Estimate 
Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update 
12 Health Care Stocks Moving In Thursday's Intraday Session 
Korro Bio Announces Preclinical Results Showing KRRO-111 Potential To Treat Both Lung And Liver Manifestations Of Alpha-1 Antitrypsin Deficiency 
HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $15 Price Target 
Korro Bio Doses First First Group Of Patients In Its Phase 1/2 Clinical Study Of KRRO-121 To Treat Hyperammonemia In Patients With Urea Cycle Disorders 
12 Health Care Stocks Moving In Friday's Intraday Session - HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $15 Price Target
Korro Bio Q2 EPS $(1.07) Beats $(1.31) Estimate - Korro Bio Announces Addition Of KRRO-111 For Potential Treatment Of AATD To Pipeline Of Therapeutic Programs In Development
Your note
Sign in to keep a note on KRRO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AGARWAL VINEET | Chief Financial Officer | Conversion of Exercise of derivative security | Nov 10, 2024 | 0 |
| BASKETT FOREST | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 21, 2024 | 0 |
| CHANG CARMEN | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 21, 2024 | 0 |
| FLORENCE ANTHONY A JR | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 21, 2024 | 0 |
| MAKHZOUMI MOHAMAD | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 21, 2024 | 0 |
| MATHERS EDWARD T. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 21, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 12.14% | 1,137,149 | 49.23M | Sep 29, 2024 |
| NEA Management Company, LLC | 11.64% | 1,090,793 | 47.22M | Sep 29, 2024 |
| Deep Track Capital, Lp | 9.07% | 850,000 | 36.80M | Sep 29, 2024 |
| FMR, LLC | 6.19% | 579,563 | 25.09M | Sep 29, 2024 |
| Citadel Advisors Llc | 5.65% | 529,173 | 22.91M | Sep 29, 2024 |
| Blackrock Inc. | 4.80% | 449,950 | 19.48M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.11% | 291,299 | 12.61M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.69% | 157,925 | 6.84M | Oct 30, 2024 |
| Fidelity Growth Company Fund | 1.47% | 137,665 | 5.96M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.86% | 80,910 | 3.50M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.66% | 62,282 | 2.70M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.45% | 42,314 | 1.83M | Oct 30, 2024 |